Company MedinCell S.A.

MEDCL

FR0004065605

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:35:11 2025-01-24 am EST			5-day change	1st Jan Change
15.98 ^EUR	+0.63%		-1.96%	-3.85%

Dec. 13	Eutelsat: delisted from the SBF 120 and CAC Mid 60 indices	CF
Dec. 13	Euroapi: delisted from the SBF 120 and CAC Mid 60 indices	CF

Business description: MedinCell S.A.

MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeqTM).

As of March 31, 2024, the company had a portfolio of 2 products in phase III clinical development and 2 products in preclinical development.

Number of employees: 131

Sales by Activity: MedinCell S.A.

Fiscal Period: March	2020	2021	2022	2023	2024
Pharmaceuticals	6M	11.78M	4.09M	13.66M	11.94M

See all business segments

Geographical breakdown of sales: MedinCell S.A.

Fiscal Period: March	2020	2021	2022	2023	2024
Israel	1.34M	4.35M	-	3.16M	5.42M
United States	1.28M	2.54M	2.41M	2.18M	1.63M
Others	228K	1.11M	-	2.57M	1.35M
Switzerland	-	-	1.31M	-	632K
Germany	-	-	368K	1.98M	-
France	-	200K	-	-	-

See all geographic segments

Managers: MedinCell S.A.

Director	Title	Age	Since
Christophe Douat CEO	Chief Executive Officer	61	2003-01-08
Stéphane Postic DFI	Director of Finance/CFO	51	2023-08-31
Richard Malamut CTO	Chief Tech/Sci/R&D Officer	65	2022-05-08
Adolfo Lopez-Noriega CTO	Chief Tech/Sci/R&D Officer	-	2016-12-31
Sébastien Magnat COO	Chief Operating Officer	-	2019-03-31

See MEDINCELL S.A. governance

Members of the board: MedinCell S.A.

Manager	Title	Age	Since
Sabri Markabi CHM	Chairman	-	2024-02-14
Philippe Guy CHM	Chairman	-	2024-03-12
Virginie Lleu BRD	Director/Board Member	-	2016-05-24
Elisabeth Kogan BRD	Director/Board Member	-	2020-12-14
Tone Kvåle BRD	Director/Board Member	56	2022-06-12

Composition of the Board of Directors

Shareholders: MedinCell S.A.

Name	Equities	%	Valuation
Mirova SA (Investment Management) 7.030 %	2,055,476	7.030 %	35 M €
Anh Nguyen 6.577 %	1,923,043	6.577 %	33 M €
Sabine Nguyen 5.580 %	1,631,423	5.580 %	28 M €
CM-CIC Innovation SASU 4.858 %	1,420,533	4.858 %	24 M €
Franck Sturtz 3.992 %	1,167,268	3.992 %	20 M €

List of MEDINCELL S.A. shareholders

Holdings: MedinCell S.A.

Name	Equities	%	Valuation
MEDINCELL S.A. 0.05%	14,754	0.05%	253,916 $

Company details: MedinCell S.A.

MedinCell SA

3, rue des Frères Lumière

34830, Jacou

+33 4 67 02 13 67

http://www.medincell.com

Other Pharmaceuticals

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
MEDINCELL S.A.	+0.63%	-1.96%	+94.88%	+93.70%	483M
ELI LILLY AND COMPANY	+2.45%	+8.22%	+23.94%	+226.68%	690B
NOVO NORDISK A/S	+7.13%	+8.13%	-14.15%	+104.43%	360B
JOHNSON & JOHNSON	+0.12%	-0.14%	-7.64%	-9.91%	353B
ABBVIE INC.	-0.22%	-0.73%	+3.70%	+28.86%	302B
MERCK & CO., INC.	-1.12%	-2.42%	-19.62%	+21.21%	244B
ROCHE HOLDING AG	+0.18%	+3.58%	+12.14%	-20.26%	243B
ASTRAZENECA PLC	+0.04%	+1.02%	+5.70%	+32.88%	211B
NOVARTIS AG	0.00%	+1.05%	-3.50%	+17.60%	199B
PFIZER, INC.	+0.31%	-0.80%	-7.91%	-49.38%	150B
Average	+0.74%	+0.09%	+8.75%	+44.58%	275.26B
Weighted average by Cap.	+0.90%	+1.42%	+2.68%	+73.61%